

Bamlanivimab Infusion Intake/Prescriber Order



Prescriber agrees:

Patient Information

- ✓ I understand this drug is not authorized for use in hospitalized coronavirus disease 2019 (COVID-19) patients, patients requiring oxygen therapy due to COVID-19, patients who require an increase in baseline oxygen flow rate due to COVID-19 and the patient or his/her guardian have provided their informed consent for the administration of Bamlanivimab.
- ✓ I understand Bamlanivimab should only be used for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization, and when the known and potential benefits to patients outweigh the known and potential risks of such product.

Patien	t Name			Date of Birth		Gender □ Male □ Female	
Facility			Room/Bed	Height	V	Weight	
Clinic	eal Information						
Date of positive COVID-19 test result			Date of symptom ons	Date of symptom onset and disease manifestation			
Adult	Patient meets at least one of th	e following criteria	(Check all that apply	<i>'</i>)			
☐ Has a body mass index (BMI) ≥35☐ Has chronic kidney disease☐ Has diabetes			 ☐ Has immunosuppressive disease ☐ Is currently receiving immunosuppressive treatment ☐ Is ≥65 years of age 				
OR □ Patient is ≥55 years of age AND has □ Cardiovascular disease OR □ Hypertension OR □ Chronic obstructive pulmonary disease/other chronic respiratory disease							
Orders							
 □ Establish vascular access, if needed (peripheral IV) □ Bamlanivimab 700mg IV in 250 mL 0.9% Sodium Chloride administered over at least 60 minutes □ Follow infusion with 0.9 % Sodium Chloride 25 mL to infuse at same rate as infusion to clear administration set of drug post infusion □ 0.9% Sodium Chloride 10 mL flush PRN □ Acute infusion reaction orders: PHARMACY TO PROVIDE IN ANAPHYLAXIS E KIT 							
Check	Drug or Treatment	Severity	Over 30 kg	Route		Note	
	Epinephrine 1 mg/mL amp (1:1000)	Moderate to Severe	□ 0.3 mg	□ SQ □ IM	☐ Repeat in	n 3-5 mins PRN	
	Diphenhydramine Oral	Mild	□ 25 mg □ 50 mg	PO			
	Diphenhydramine 50mg/mL vial	Moderate to Severe	□ 25 mg □ 50 mg	Slow IV or IM		n 3-5 mins PRN se = 50 mg	
	Methylprednisolone Sodium Succinate 125mg/2mL	Moderate to Severe	125 mg	□ IM □ IV	x 1 dose		
	Albuterol inhaler	Moderate to Severe	90 mcg/act	INHALER	1-2 puffs PR	RN	
Facilit	y Nurse to call/fax above informat	ion to physician/LIP. I	Either have physician	/LIP sign below	ı, or obtain a	s a telephone order.	
Nurse			Print Name			Date	
Physician/prescriber			Print Name			Date	
Pharmacy Name: FAX COMPLETED FORM TO () -							